|
|
|
| Diagnosis value analysis of ovarian cancer by combining ultrasonic with serum CA125 |
| WANG Li-hua1, CHEN Fu-mei2, ZHONG Yan-mi1, SONG Hai-yun1 |
1. Qilu Hospital of Shandong University(Qingdao), Qingdao Shandong 266035, China;
2. Department of Ultrasound， Jinan Third People’s Hospital, Jinan 250101, China |
|
[1]Buys S, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian cancer screening randomized controlled trial[J]. JAMA, 2011, 305(22): 2295.
[2]Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
[3]戴晴. 卵巢恶性肿瘤的超声评价及研究进展[J]. 肿瘤影像学，2016，25（1）：1-4.
[4]娄国平，李显东，张昭勇，等. 联合应用多项肿瘤标志物诊断卵巢上皮性癌的价值[J]. 中国医药，2016，11（1）：101-105.
[5]Medeiros LR, Rosa DD, Rosa MI, et al. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review[J]. Eur J Obstet Gynecol Reprod Biol, 2009, 142(2): 99-105.
[6]岳娟，刘菲，李艳红. 卵巢癌早期诊断的血清肿瘤标志物研究进展[J]. 国际妇产科学杂志，2015，42（5）：560-563.
[7]辜卫红，胡天惠，薛涛. 血清CA125、HE4联合阴道彩色多普勒在卵巢癌高危人群早期筛查中的临床价值[J]. 重庆医学，2017，46（12）：1613-1615. |
|
|
|
